Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Dexcom, Inc. for allegedly misleading investors about the safety and reliability of its continuous glucose monitoring systems, specifically the G6 and G7 models [1][2]. Allegations - The lawsuit claims that Dexcom made unauthorized material design changes to the G6 and G7 systems, which compromised their reliability and posed health risks to users [2]. - It is alleged that Dexcom overstated the enhancements and reliability of the G7 system while downplaying the severity of issues related to adulterated devices [2]. - The complaint suggests that these actions have exposed Dexcom to increased regulatory scrutiny and potential legal repercussions [2]. Impact of Hunterbrook Report - A report published by Hunterbrook on September 18, 2025, highlighted severe health risks associated with the G7 devices, including incidents of hospitalization and death linked to inaccurate glucose readings [3]. - Following the release of this report, Dexcom's stock price dropped by $8.99 per share, or 11.76%, closing at $67.45 on September 19, 2025 [3]. Class Action Participation - Investors who purchased Dexcom securities between July 26, 2024, and September 17, 2025, may be eligible to participate in the class action, with a deadline for lead plaintiff submissions set for December 29, 2025 [4].